266 related articles for article (PubMed ID: 29673809)
1. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues".
Sansone VA; Pane M; Messina S; Bruno C; D'Amico A; Albamonte E; Catteruccia M; Sframeli M; Pedemonte M; Vita G; Bertini E; Mercuri E;
Eur J Paediatr Neurol; 2018 Jul; 22(4):729-731. PubMed ID: 29673809
[No Abstract] [Full Text] [Related]
2. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center.
La Foresta S; Faraone C; Sframeli M; Vita GL; Russo M; Profazio C; Rulli I; Gitto E; Versaci A; Messina S; Vita G
Neurol Sci; 2018 Nov; 39(11):1961-1964. PubMed ID: 30043247
[TBL] [Abstract][Full Text] [Related]
4. Anesthetic management of pediatric patients undergoing intrathecal nusinersen administration for treatment of spinal muscular atrophy: A single-center experience.
Brollier LD; Matuszczak M; Marri T; Carbajal JG; Moorman AT; Sorial EM; Jain R
Paediatr Anaesth; 2021 Feb; 31(2):160-166. PubMed ID: 32623818
[TBL] [Abstract][Full Text] [Related]
5. The Complex Spine in Children with Spinal Muscular Atrophy: The Transforaminal Approach-A Transformative Technique.
Towbin R; Schaefer C; Kaye R; Abruzzo T; Aria DJ
AJNR Am J Neuroradiol; 2019 Aug; 40(8):1422-1426. PubMed ID: 31296522
[TBL] [Abstract][Full Text] [Related]
6. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.
Aragon-Gawinska K; Seferian AM; Daron A; Gargaun E; Vuillerot C; Cances C; Ropars J; Chouchane M; Cuppen I; Hughes I; Illingworth M; Marini-Bettolo C; Rambaud J; Taytard J; Annoussamy M; Scoto M; Gidaro T; Servais L
Neurology; 2018 Oct; 91(14):e1312-e1318. PubMed ID: 30158155
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
8. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1.
Pechmann A; Langer T; Wider S; Kirschner J
Eur J Paediatr Neurol; 2018 Jan; 22(1):122-127. PubMed ID: 29208343
[TBL] [Abstract][Full Text] [Related]
9. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen.
Bielsky AR; Fuhr PG; Parsons JA; Yaster M
Paediatr Anaesth; 2018 Dec; 28(12):1105-1108. PubMed ID: 30284761
[TBL] [Abstract][Full Text] [Related]
10. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.
Ergenekon AP; Yilmaz Yegit C; Cenk M; Gokdemir Y; Erdem Eralp E; Ozturk G; Unver O; Kenis Coskun O; Karadag Saygi E; Turkdogan D; Karadag B
Pediatr Int; 2022 Jan; 64(1):e15175. PubMed ID: 35522792
[TBL] [Abstract][Full Text] [Related]
11. Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen.
Xiao L; Chiang J; Castro-Codesal M; Kolski H; Bedi P; Al Amrani F; Gonorazky HD; Amin R;
Pediatr Pulmonol; 2023 Jan; 58(1):161-170. PubMed ID: 36193036
[TBL] [Abstract][Full Text] [Related]
12. Computed-tomography-guided transforaminal intrathecal nusinersen injection in adults with spinal muscular atrophy type 2 and severe spinal deformity. Feasibility, safety and radiation exposure considerations.
Spiliopoulos S; Reppas L; Zompola C; Palaiodimou L; Papadopoulou M; Filippiadis D; Palialexis K; Ploussi A; Efstathopoulos E; Tsivgoulis G; Brountzos E
Eur J Neurol; 2020 Jul; 27(7):1343-1349. PubMed ID: 32250518
[TBL] [Abstract][Full Text] [Related]
13. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.
Lavie M; Rochman M; Sagi L; Yerushalmy Feler A; Ovadia D; Cahal M; Be'er M; Sadot E; Fattal-Valevski A; Amirav I
Pediatr Pulmonol; 2022 Mar; 57(3):686-694. PubMed ID: 34921596
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
[TBL] [Abstract][Full Text] [Related]
16. Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
Le Goff L; Seferian A; Phelep A; Rippert P; Mathieu ML; Cances C; de Lattre C; Durigneux J; Gousse G; Vincent-Genod D; Ribault S; Gomez Garcia de la Banda M; Quijano-Roy S; Sarret C; Servais L; Vuillerot C
Neurol Sci; 2023 Jan; 44(1):329-337. PubMed ID: 36175810
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen Administration Via an Intrathecal Port in a 16-Year-Old Spinal Muscular Atrophy Patient with Profound Scoliosis.
Flotats-Bastardas M; Linsler S; Zemlin M; Meyer S
Pediatr Neurosurg; 2020; 55(1):54-57. PubMed ID: 31722365
[TBL] [Abstract][Full Text] [Related]
18. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
[TBL] [Abstract][Full Text] [Related]
19. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients.
Wurster CD; Winter B; Wollinsky K; Ludolph AC; Uzelac Z; Witzel S; Schocke M; Schneider R; Kocak T
J Neurol; 2019 Jan; 266(1):183-194. PubMed ID: 30460449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]